Evidence map›Paper›PMID 37375297›Full record

ArticleMolecules (Basel, Switzerland)2023

Tricyclic Diterpenoids Selectively Suppress Androgen Receptor-Positive Prostate Cancer Cells.

Inderpal Sekhon, Guanglin Chen, Keyara Piri, Seiji Shinkawa, Dennis Ashong, Qiang Zhang, Guangdi Wang, Qiao-Hong Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Inderpal SekhonDepartment of Chemistry & Biochemistry, California State University, Fresno, CA 93740, USA.
Guanglin ChenDepartment of Chemistry & Biochemistry, California State University, Fresno, CA 93740, USA.
Keyara PiriDepartment of Chemistry & Biochemistry, California State University, Fresno, CA 93740, USA.ORCID 0000-0003-0084-7183
Seiji ShinkawaDepartment of Chemistry & Biochemistry, California State University, Fresno, CA 93740, USA.
Dennis AshongDepartment of Chemistry & Biochemistry, California State University, Fresno, CA 93740, USA.
Qiang ZhangDepartment of Chemistry and RCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, LA 70125, USA.
Guangdi WangDepartment of Chemistry and RCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, LA 70125, USA.
Qiao-Hong ChenDepartment of Chemistry & Biochemistry, California State University, Fresno, CA 93740, USA.ORCID 0000-0001-6753-1824
California State University, Fresno · USXavier University of Louisiana · US

Funding

Xavier RCMI Renewal Application-Research Infrastructure CoreU54MD007595 · NIMHD · XAVIER UNIVERSITY OF LOUISIANA · PI Guangdi Wang, Christopher Williams · 2019 to 2026
$41.9M
Xavier's RCMI Cancer Research ProgramG12MD007595 · NIMHD · XAVIER UNIVERSITY OF LOUISIANA · PI D'AMOUR, GENE, WANG, GUANGDI · 2012 to 2018
$15.7M
Introduction to Quantitative Genomic Analysis - A CUREs ApproachR25GM131956 · NIGMS · CALIFORNIA STATE UNIVERSITY FRESNO · PI KRISHNAN, VISWANATHAN V · 2019 to 2023
$2.5M
Development of Research And Writing Skills (DRAWS): A tool for broader assessment to enhance research and research trainingT32GM137948 · NIGMS · CALIFORNIA STATE UNIVERSITY FRESNO · PI CARVAJAL CARMONA, LUIS GUILLERMO, KRISHNAN, VISWANATHAN V · 2020 to 2024
$1.1M
NIGMS NIH HHS R25 GM131956NIGMS NIH HHS T32 GM137948NIH HHS G12MD007595NIMHD NIH HHS G12 MD007595NIMHD NIH HHS U54 MD007595
6 · The paper itself

Abstract

Androgen receptor (AR) is a viable therapeutic target for lethal castration-resistant prostate cancer (CRPC), because the continued progression of CRPC is mainly driven by the reactivation of AR transcriptional activity. The current FDA-approved AR antagonists binding to ligand binding domain (LBD) become ineffective in CRPC with AR gene amplification, LBD mutation, and the evolution of LBD-truncated AR splice variants. Encouraged by the fact that tricyclic aromatic diterpenoid QW07 has recently been established as a potential

Indexed as

DiterpenesProstatic Neoplasms, Castration-ResistantAndrogen Receptor AntagonistsBenzamidesCell Line, TumorHumansMaleNitrilesPhenylthiohydantoinReceptors, AndrogenAndrogen Receptor AntagonistsBenzamidesDiterpenesenzalutamideNitrilesPhenylthiohydantoinReceptors, Androgenandrogen receptor antagonistditerpenoidN-terminal domainprostate cancerQW07

Identifiers

PMID37375297
PMCPMC10300971
OpenAlexW4380684729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.